Transforming Immunotherapy:
Targeting oxMIF in Cancer & Chronic Inflammation
oxMIF: we discovered it, we named it, we are drugging it
In recent years, significant advancements have tackled previously elusive therapeutic targets, with the potential to redefine patient care standards. OncoOne is at the forefront, with the groundbreaking discovery of oxMIF, an oxidized, disease-specific variant of the well-known yet enigmatic cytokine Macrophage Migration Inhibitory Factor (MIF). This breakthrough fuels our mission to harness the full potential of this ‘original cytokine’, aiming to enhance patient outcomes in cancer and inflammation via our innovative anti-oxMIF antibody pipeline.
experienced
flexible
innovative
responsive
collaborative
Therapeutic Areas:
Targeting oxMIF in Cancer and Chronic Inflammation
Oncology
OncoOne is developing ON203, an enhanced second-generation anti-oxMIF antibody, designed to address the treatment needs of patients facing solid tumors with substantial unmet medical requirements, encompassing tumors of the colon, lung, and ovaries. Its mechanism of action enables its use both as a monotherapy and in combination with standard-of-care treatments
Chronic Inflammation
Recent Publications
- Ferhat M. et al. (2023) “The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis”, European Journal of Pharmacology, Volume 956, 5 October 2023, 175997. https://doi.org/10.1016/j.ejphar.2023.175997
- Rossmueller, G. et al. (2023) ‘Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic’, Molecular Cancer Therapeutics, pp. OF1–OF15. https://doi: 10.1158/1535-7163.MCT-22-0676.